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AbstrACt
Introduction In the past decades, mortality due to breast 
cancer has declined considerably in Switzerland and 
other developed countries. The reasons for this decline 
remain controversial as several factors occurred almost 
simultaneously, including important advances in treatment 
approaches, breast cancer awareness and the introduction 
of mammography screening programmes in many European 
countries. In Switzerland, mammography screening 
programmes (MSPs) have existed in some regions for 
over 20 years but do not yet exist in others. This offers the 
possibility to analyse its effects with modern spatiotemporal 
methodology. We aimed to assess the spatiotemporal 
patterns and the effect of MSPs on breast cancer mortality.
setting Switzerland.
Participants The study covers breast cancer deaths of 
the female population of Switzerland during the period 
1969–2012. We retrieved data from the Swiss Federal 
Statistical Office aggregated on a small-area level.
Design We fitted Bayesian hierarchical spatiotemporal 
models on death rates indirectly standardised by 
national references. We used linguistic region, degree 
of urbanisation, duration of population-based screening 
programmes and socioeconomic index as covariates.
results In Switzerland, breast cancer mortality in women 
slightly increased until 1989–1992 and declined strongly 
thereafter. Until 2009–2012, the standardised mortality 
ratio declined to 57% (95% CI 54% to 60%) of the 
1969–1972 value. None of the other coefficients of the 
spatial regressions had a significant effect on breast cancer 
mortality. In 2009–2012, no region had significantly elevated 
or reduced breast cancer mortality at 95% credible interval 
level compared with the national mean.
Conclusion There has been a strong reduction of breast 
cancer mortality from the 1990s onwards. No important 
spatial disparities were observed. The factors studied 
(urbanisation, language, duration of population-based 
MSP and socioeconomic characteristics) did not seem to 
have an influence on them. Low participation rates and 
opportunistic screening use may have contributed to the 
low impact of MSPs.
IntroDuCtIon 
In Switzerland, breast cancer is the most 
frequently diagnosed cancer in women,1 it is 
the leading cause of cancer-related deaths2 
and of premature mortality for Swiss women.3 
Mortality due to breast cancer has declined 
considerably in the past decades in Switzer-
land and other developed countries.4 The 
reasons for the decline remain controversial 
because several factors including important 
advances in treatment approaches, breast 
cancer awareness and the introduction of 
mammography screening programmes in 
many European countries occurred almost 
simultaneously.
Some randomised controlled studies5 
have demonstrated a breast cancer mortality 
reduction of 20% for women invited for 
breast cancer screening. However, they were 
conducted in the 1970s to 1980s. Since then, 
many advances in therapies have been made 
and adopted6 so that some authors doubt that 
the difference would persist under present 
conditions. Therefore, often used historical 
strengths and limitations of this study
 ► A modern Bayesian spatial model was used 
to improve estimation of an unstable rate by 
‘borrowing’ strength from its neighbours.
 ► The model is capable of assessing the significance 
of risk factors while also taking the geographical 
correlation into account.
 ► Switzerland with its homogeneous health system 
and different regional screening policies provides an 
ideal setting for assessing the impact of population-
based mammography screening programmes.
 ► Data on the geographical differences in 
opportunistic screening use and therefore overall 
screening participation are not available, where 
opportunistic screening use is estimated to be high 
and programme participation less than 50%.
 ► The ecological study design does not allow an 
assessment of the combined impact of participation 
in and type (programme vs opportunistic) of 
mammography screening.
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prescreening control groups are not best suited to disen-
tangle these effects. Autier et al7 compared countries in 
Europe but a criticism was that different countries may 
have different health systems. Kalager et al8 used compar-
ison groups in Norway and showed that only a third of the 
total mortality reduction could be attributed to mammog-
raphy screening. However, a short observation period was 
used. Olsen et al9 confirmed these results in principle with 
the same data but with a somewhat longer follow-up dura-
tion. In addition, in a setting where voluntary screening 
is assumed to be high, it is unknown what the effect an 
organised screening programme would be for the popu-
lation as a whole.
In Switzerland, with its homogenous health system, 
these pitfalls can be avoided. Switzerland is a small 
confederation of 26 relatively autonomous states called 
cantons with somewhat low inequalities10 and many 
health and cancer-related resources.11–13 Although the 
healthcare system is homogeneous in providing universal 
and rapid access to and use of almost unlimited health-
care resources, some healthcare policies are developed at 
the cantonal level; in particular, the decision to initiate a 
population-based mammography screening programme. 
These programmes were implemented in Switzerland at 
different times over the past two decades. The first Swiss 
mammography pilot programme was established in 1993 
in the French-speaking canton of Vaud. However, it was 
only in 2010 that the first organised programme in a 
German-speaking canton (St Gallen) started.
In breast cancer incidence, cantonal differences are 
well known and have been attributed to the differen-
tial use of opportunistic or organised mammography 
screening.14 In addition, considerable differences in 
health and health-related behaviour that affect the risk of 
breast cancer, including alcohol intake and a healthy diet, 
have been reported for the Swiss language regions,15 16 
as well as differences in the age at first childbirth and 
number of children born to a mother.17 Differences in 
access to mammography screening and in lifestyle may 
be reflected in spatiotemporal differences in both breast 
cancer incidence and mortality, whereas only the latter 
will reflect the management of breast cancer.
In contrast, breast cancer mortality studies in Swit-
zerland showed contradictory results. Bulliard et al18 
observed a steeper decrease from 1980 to 2002 in 55–74-
year olds in French-speaking regions where popula-
tion-based mammography screening started earlier. 
In a recent study,19 we presented the spatiotemporal 
trends of female gender-related cancer mortality in 
Switzerland by age group. The geographical differences 
found were small. We observed a differential decline in 
breast cancer mortality by age. The decline was highest 
in women younger than 50 and lower in women 75 or 
older. A similar pattern was observed in other European 
countries4 and attributed to early detection by mammog-
raphy and to improved treatment.20–22 However, it was not 
clear to what extent improvements in survival could have 
affected the age at death. It was difficult to evaluate a shift 
of deaths into the next higher age group and the influ-
ence of screening programmes based on using fixed age 
groups rather than cohorts.
In the present study, we aimed to assess the spatiotem-
poral patterns in breast cancer mortality and specifically 
the effect of population-based mammography screening 
programmes on it. We corrected for urbanisation for 
which a mortality gradient was described23 and addition-
ally for area-based socioeconomic factors, which may have 
influenced results in the previous study.
MethoDs
Data sources
The Swiss Federal Statistical Office provided data on 
female breast cancer mortality, electronically available 
for the period of 1969–2012. The anonymised data 
included sex, age, year of birth and death for each indi-
vidual, nationality, municipality of residence, the cause 
of death and comorbidities. The cause of death and 
comorbidities were coded centrally from death certifi-
cates using the eighth revision of the International Clas-
sification of Diseases (ICD) for deaths until 1994, and 
the 10th revision for deaths that occurred afterwards. 
The transition to the 10th revision of the ICD was accom-
panied by changes in death certificate coding practices 
(priority rules). We used age and cancer site-specific 
correction factors as proposed by Lutz et al24 for the death 
counts. We included all cases coded with main causes of 
death being cancer of the female breast (ICD-10 C50.0–
C50.9). According to federal regulations, mortality data 
excluding a person’s identifying information can be 
used in epidemiological studies without additional ethics 
committee approval.
The administrative borders of Swiss municipalities 
define the smallest geographical unit for which data were 
available. There are around 2500 municipalities in the 
country with a median population of 740 inhabitants in 
1970 and 1150 in 2010.
Aggregated population data by age and area unit were 
extracted from the census that takes place in Switzerland 
every 10 years. The last census was conducted in 2010. 
Because of missing detailed intercensal population data, 
we aggregated the mortality data in five 4-year periods 
around the census years, that is, 1969–1972, 1979–1982, 
1989–1992, 1999–2002 and 2009–2012, in which popu-
lation was assumed to be constant and identical to the 
census year.
From the same source, we retrieved data on language 
region (German, French and Italian and Romansh) and 
urbanisation (rural/urban). We obtained information 
on population-based screening programmes from the 
Swiss Federation of Cancer Screening Programmes25 
and categorised their duration in the census years into 
‘no programme’, ‘0–4 years’ and ‘5+ years’. Data on 
socioeconomic position by municipality were provided 
by the Swiss National Cohort26 based on the census data 
of 2000.
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Table 1 shows the observed number of deaths and 
mortality rates for each of the covariates.
statistical methods
As a small area geographical unit, we used the munici-
pality borders as of 2012. We used municipality transition 
protocols from the Federal Statistical Office to align all 
data to this structure.
We investigated mortality for all ages combined in a 
spatial and a non-spatial model, one time for the five time 
periods from 1969 to 2012 to assess possible non-linear 
time trends and another time only for the period of 
2009–2012.
For the spatial model, we used the Bayesian hierarchical 
spatiotemporal Poisson model formulations as described 
in Herrmann et al,19 fitted on the number of deaths aggre-
gated by small area and year, with the mean being equal 
to the product of the expected death count and age-stan-
dardised mortality rate. The indirect standardisation used 
5-year age intervals. Expected mortality counts for each 
small area and year were obtained from the study popu-
lation using nationwide age-specific mortality rates, once 
for all periods and again only for the period of 2009–2012. 
The small area-specific random effects were modelled via 
conditional autoregressive models to filter out the noise 
and highlight the observed patterns. The deviance infor-
mation criterion (DIC) was used to select the regression 
model from Poisson, zero-inflated Poisson and negative 
binomial regression models. The DIC was lowest with the 
Poisson regression model.
We accounted for differences that were influenced by 
linguistic region, life in rural or urban areas, screening 
programme duration and socioeconomic position. 
These analyses are used to indicate whether there are 
significant differences in cancer mortality for each of 
the above covariates, assessed by 95% Bayesian Credible 
Intervals.
Patient involvement
No patients were involved in this study.
results
In Switzerland, more than 61 000 women died from 
breast cancer between 1969 and 2012. Table 2 presents 
the results of the regressions including all time periods 
Table 1 Observed numbers of female breast cancer deaths and mortality rates per 100 000 PY by period and municipality 
characteristics. The total numbers before 1994 include the correction factors
Total no. of breast 
cancer deaths %
Yearly population 
(×1000) Crude rate ASR
P value for ASR 
homogeneity
Period p<0.01
  1969–1972 4177 16 3180 32.8 32.0
  1979–1982 4953 19 3251 38.1 32.5
  1989–1992 5968 23 3483 42.8 32.6
  1999–2002 5261 20 3720 35.4 25.4
  2009–2012 5574 21 3993 34.9 22.3
Language p=0.56
  German 18 613 72 12 622 36.9 28.5
  French 5915 23 4159 35.6 27.7
  Italian/Roman 1405 5 847 41.5 28.9
Urbanisation level p=0.08
  Rural 6172 24 4491 34.4 26.9
  Urban 19 761 76 13 137 37.6 28.8
Years of population-based screening* p=0.53
  No programme 4246 76 2942 36.1 22.6
  1–4 years 169 3 115 36.9 23.4
  5+ years 1159 21 936 31.0 21.2
Socioeconomic index quartiles p=0.24
  Q1 (lowest) 1999 8 1478 33.8 26.4
  Q2 4313 17 3033 35.6 28.1
  Q3 5864 23 4199 34.9 27.7
  Q4 (highest) 13 757 53 8919 38.6 29.0
*Only for the period 2009–2012, length of screening refers to the year 2010.
ASR, Age Standardised mortality Rate; PY, Person Years. 
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and time trends. In Switzerland, breast cancer mortality 
in women slightly increased until the 1989–1992 period 
and has declined strongly since. Until the most recent 
period (2009–2012), the SMR has fallen to 57% of the 
1969–1972 period’s value, both in the non-spatial and the 
spatial models. The trends and geographical differences 
are visualised in figure 1.
From the covariates studied, only the year of death 
and the urbanisation level in the non-spatial model had 
a significant impact when investigating all periods. An 
urban environment was associated with a 5% elevated 
SMR (3% in the spatial model) compared with a rural 
environment.
Limiting the analysis to the period of 2009–2012, none 
of the regression factors had a significant effect on breast 
cancer mortality (table 3).
Most SMR ratios of the non-spatial and the spatial 
model showed nearly identical values. The length of a 
screening programme and the French language region 
showed slightly higher values, but the differences were 
not significant.
In the 2009–2012 period, no region had a significantly 
higher or lower breast cancer mortality rate at 95% CI 
level compared with the national mean (figure 2). A 
map with covariate-adjusted smoothed SMR values is not 
shown because there was no information gain. The covari-
ates are not significant and the geographical patterns are 
the same as for the smoothed SMR values.
The socioeconomic index value for the municipalities 
ranged from 28 to 85, where 25% of municipalities were 
below 55% and 25% above 66.
DIsCussIon
In the past decades, breast cancer mortality has nearly 
halved in Switzerland when considering all ages together. 
This trend, including the shift from increasing to 
decreasing rates around the period of 1989–1992, has been 
observed in several other European countries.4 Although 
significant spatial differences in breast cancer incidence 
are well described for Switzerland, we have not found any 
significant differences in breast cancer mortality in any 
of the periods studied. We have not observed any general 
significant differences between regions classified by dura-
tion of screening programmes, urbanisation, language 
and socioeconomic position. In addition, when limiting 
the analysis to the most recent period (2009–2012), none 
Table 2 Spatiotemporal model estimates of age-specific 
breast cancer mortality in Switzerland from the 1969–1972 
period to the 2009–2012 period. Bold values denote age-
standardised mortality ratio significantly different from 1. 
Spatial variation (SD of spatial random effects): a value of 0 




  1969–1972 1.00 1.00
  1979–1982 1.01 (0.97 to 1.05) 1.01 (0.97 to 1.05)
  1989–1992 1.04 (1.00 to 1.09) 1.05 (1.01 to 1.09)
  1999–2002 0.81 (0.78 to 0.84) 0.81 (0.78 to 0.85)
  2009–2012 0.57 (0.54 to 0.59) 0.57 (0.54 to 0.60)
Language
  German 1.00 1.00
  French 0.99 (0.95 to 1.02) 1.02 (0.92 to 1.14)
  Italian/Roman 1.01 (0.96 to 1.08) 0.99 (0.83 to 1.16)
Urbanisation level
  Rural 1.00 1.00
  Urban 1.05 (1.01 to 1.08) 1.03 (0.98 to 1.08)
Years of population-based screening
  0, 1–4 years 1.00 1.00
  5+years 0.95 (0.88 to 1.03) 0.95 (0.88 to 1.04)
Socioeconomic index
  Per 10-point 
increase 1.02 (0.99 to 1.04) 1.02 (0.98 to 1.05)
Spatial variation 0.21 (0.18 to 0.24)
SMR, standardised mortality ratio.
Figure 1 Development of age-standardised breast cancer 
mortality and spatial differences therein among time. Values 
are calculated and smoothed in relation to the all-period 
combined mortality. Darker colours represent a higher 
mortality for the specific age structure and population in that 
area and time period. SMR, standardised mortality ratio.
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of the factors are significant. In fact, at 95% CI, none of 
the regions have a significantly elevated or reduced breast 
cancer mortality compared with the national mean.
There are several factors that explain why the signifi-
cant differences in incidence do not translate into corre-
sponding mortality differences. Most importantly, risk 
factors such as health and health-related behaviour that 
are reported to be different for the language regions16 
affect incidence but are not necessarily linked to 
mortality.27 That is, while a temporary increase in the use 
of hormone replacement therapy has led to an increase 
in breast cancer incidence, many of those tumours have 
a favourable prognosis and might have influenced breast 
cancer mortality only marginally.28 Accordingly, the 
French language region, despite earlier implementation 
of mammography screening programmes, does not show 
a relevant impact on breast cancer mortality in our study.
Because screening has been identified as a potential 
source of mortality reduction,21 we also included data 
on population-based screening programme duration. 
However, our study did not show a significant effect on 
mortality on the population level. The reasons for this 
are probably manifold and may include factors such 
as screen-detected cancers being mainly of low stage, 
many women having not participated in the screening 
programmes or having chosen to undergo opportunistic 
screening. In addition, the effect of advances in diagnosis 
and therapy on mortality is quite strong and may have 
outweighed benefits from population-based screening 
programmes, as suggested by Autier et al.29 Moreover, the 
level of opportunistic screening in Switzerland has been 
described to be quite high,30 but data on the geographical 
differences in opportunistic screening use, and therefore 
overall screening participation, are not available. Data on 
participation in population-based screening programmes 
are published in a national monitoring report showing 
that participation rates of the programmes are close to the 
combined mean of 47.8%.31The ecological study design 
does not allow the assessment of the combined impact of 
participation in and type (programme vs opportunistic) 
of mammography screening or the impact of stage of 
tumour at diagnosis and mortality at an individual level. 
For the above reasons, the interpretability with regard to 
screening is limited. In addition, we had to group into 0–4 
years and 5+ years of screening, which was done to avoid 
overfitting issues. There are only a few regions that are in 
close proximity to each other with 10+ years of screening 
in the 2009–2012 period only (see online supplementary 
figure A1).
The present study is an in-depth analysis of our previous 
study,19 focusing on breast cancer mortality using an addi-
tional year of more recent data. We were also interested 
in the effects on the population as a whole. The applied 
methodology of age standardisation suits this by taking 
advantage of the actual age structure rather than of a 
standard population.
The non-significant fixed effect of socioeconomic posi-
tion is in line with the results of Panczak et al.32 The addi-
tional correction served the disentanglement of affluence 
from the urbanisation parameter—which is connected 
with access to medical services—and further possible 
distortions.33
A strength of Bayesian spatial models is their 
‘smoothing’ or improvement of estimation of an unstable 
rate by ‘borrowing’ strength from its neighbours.34 These 
models can also assess the significance of risk factors, 
taking into account the geographical correlation and are 
able to show spatial patterns after adjusting for geograph-
ical differences in certain risk factors. By adding a time 
dimension, Bayesian spatiotemporal models indicate 
changes of geographical patterns over time and deter-
mine how a disease evolves in different regions and 
different groups of the population (age, language or 
Table 3 Spatiotemporal model estimates of age-
standardised breast cancer mortality in Switzerland in the 
2009–2012 period. Bold values denote age-standardised 




  German 1.00 1.00
  French 1.00 (0.86 to 1.15) 1.03 (0.81 to 1.33)
  Italian/Roman 1.01 (0.87 to 1.16) 1.00 (0.68 to 1.37)
Urbanisation level
  Rural 1.00 1.00
  Urban 0.97 (0.89 to 1.06) 0.97 (0.89 to 1.07)
Years of population-based screening
  0, 1–4 years 1.00 1.00
  5+ years 0.95 (0.82 to 1.11) 0.99 (0.78 to 1.23)
Socioeconomic index
  Per 10-point 
increase 1.03 (0.97 to 1.09) 1.03 (0.95 to 1.10)
Spatial variation 0.29 (0.24 to 0.35)
SMR, standardised mortality ratio.
Figure 2 Geographical differences in age-standardised 
breast cancer mortality in 2009–2012. *Significance is 
denoted as values significantly different at 95% CI from 1, the 
national mean. SMR, standardised mortality ratio.
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affluence groups). These models have provided a state-
of-the-art modelling approach over the last 15 years for 
assessing spatio-temporal patterns and trends. We have 
not observed that coefficients in our analysis have shrunk 
towards zero when including geographical correlation 
as hypothesised by Hodges and Reich.35 In fact, in the 
spatial model for the 2009–2012 period, the impact of the 
French language region is 1.03 compared with 1.00 in the 
non-spatial model. However, we have included the results 
of the non-spatial models as well.
ConClusIon
There has been a strong reduction of breast cancer 
mortality from the 1990s onwards. Geographical differ-
ences are present, but at a moderate level with no signif-
icant differences in the overall mean. In addition, they 
are not explained by the duration of population-based 
screening programmes, socioeconomic position, urban-
isation and language region. Low participation rates and 
opportunistic screening use may have contributed to the 
low impact of mammography screening programmes. 
Continuous evaluation of geographical patterns of 
breast cancer mortality using modern spatiotemporal 
methodology is necessary for evaluating the efficacy of 
programmes.
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